Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.14 USD | +1.71% | -2.38% | +1.44% |
05:34pm | Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study | MT |
May. 06 | Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.44% | 2.6B | |
+29.13% | 49.18B | |
+0.96% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.29% | 26.09B | |
-22.70% | 18.71B | |
+8.15% | 13.26B | |
+32.02% | 12.32B | |
-0.71% | 11.99B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Transcript : Celldex Therapeutics, Inc. - Special Call